ArticleMolecular medicine reports2020
Downregulated miR‑130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin.
Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Exosomal miR-92b-5p regulates N4BP1 to enhance PTEN mono-ubiquitination in doxorubicin-resistant AML.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways.Annals of hematology · 2024Review
- Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling.Cancer science · 2023Article
- Mechanism of Action of Decitabine in the Treatment of Acute Myeloid Leukemia by Regulating LINC00599.Analytical cellular pathology (Amsterdam) · 2023Article
- Analysis of serum circulating MicroRNAs level in Malaysian patients with gestational diabetes mellitus.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA (miR)‑130a has been reported to promote cancer growth; however, its role during acute myeloid leukemia (AML) is not completely understood. In the present study, the effects of miR‑130a on the sensitivity of AML cells to Adriamycin (Adr) were investigated. 5‑Aza‑2'‑deoxycytidine (5‑Aza‑dC) was used to stimulate Adr resistance in AML cells, and cell viability and miR‑130a expression were determined using the Cell Counting Kit‑8 (CCK‑8) assay and reverse transcription‑quantitative PCR, respectively. miR‑130a overexpression and knockdown in Adr‑resistant AML cells was performed to investigate the proliferative and invasive abilities of the cells using CCK‑8 and Transwell assays, respectively. Furthermore, the effects of miR‑130a on the expression of epithelial‑mesenchymal transition (EMT)‑related proteins in Adr‑resistant AML cells were detected using western blot analysis. Pre‑treatment with 5‑Aza‑dC enhanced the cell viability and miR‑130a expression of Adr‑treated AML cells. Adr and miR‑130a expression showed a dose‑dependent relationship, with miR‑130a expression decreasing with increasing Adr concentrations. Moreover, miR‑130a overexpression alleviated the inhibitory effects of Adr on cell viability and invasion, while miR‑130a knockdown enhanced the sensitivity of AML cells to Adr. Furthermore, Adr exerted an inhibitory effect on EMT in AML cells, which was rescued by miR‑130a overexpression and enhanced by miR‑130a knockdown. miR‑130a knockdown also increased the sensitivity of AML cells to Adr by decreasing cell viability, invasion and EMT. Therefore, miR‑130a knockdown is a potential therapeutic strategy for Adr‑resistant AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.